# US 2025/0144077 A1 · Dosage regimen for thrombopoietin receptor agonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144077 A1
- Document ID: US20250144077A1
- Status: Published application
- Kind: A1
- Application number: 18/832,422
- Filed: 2023-01-19
- Published: 2025-05-08
- Earliest claimed: 2022-01-25
- Assignees: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Applicants: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Inventors: Hongda LIN; Kai SHEN; Yaqi SHEN; Yue HU; Yanhua DING
- Web page: https://patentgrep.com/patent/US20250144077A1

## CPC

- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/655: Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to a dosage regimen for a thrombopoietin receptor agonist. In particular, the present disclosure relates to a method of administering hetrombopag or a pharmaceutically acceptable salt thereof to a patient in need, the patient suffering from mild liver injury or moderate liver injury.

## Claims

### Claim 1

A method for administering herombopag or a pharmaceutically acceptable salt thereof to a patient in need thereof, wherein the patient has a mild hepatic impairment; the method comprises: administering to the patient having a mild hepatic impairment a therapeutically effective amount of herombopag or the pharmaceutically acceptable salt thereof, wherein an initial dose of the herombopag or the pharmaceutically acceptable salt thereof is unadjusted as compared to an initial dose administered to a patient having normal liver function.

### Claim 2

A method for administering herombopag or a pharmaceutically acceptable salt thereof to a patient in need thereof, wherein the patient has a moderate hepatic impairment; the method comprises: administering to the patient having a moderate hepatic impairment a therapeutically effective amount of herombopag or the pharmaceutically acceptable salt thereof, wherein an initial dose of the herombopag or the pharmaceutically acceptable salt thereof is less than an initial dose administered to a patient having normal liver function or a mild hepatic functional impairment.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the initial dose of the herombopag or the pharmaceutically acceptable salt thereof administered to the patient having a moderate hepatic impairment is 10%-90% less than the initial dose administered to the patient having normal liver function or a mild hepatic functional impairment.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the initial dose of the herombopag or the pharmaceutically acceptable salt thereof administered to the patient having a moderate hepatic impairment is 50% less than the initial dose administered to the patient having normal liver function or a mild hepatic functional impairment.

### Claim 5

A method for administering herombopag or a pharmaceutically acceptable salt thereof to a patient in need thereof, wherein administering a dose of the herombopag or the pharmaceutically acceptable salt thereof to a patient having a mild, moderate, or severe hepatic impairment results in higher exposure than administering the dose to a patient having normal liver function.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the exposure is measured by Cmax or AUC0-∞.

### Claim 7 (depends on 6)

The method according to claim 6, wherein
a therapeutically effective amount of the herombopag or the pharmaceutically acceptable salt thereof is administered to the patient having a mild hepatic impairment, wherein administering herombopag to the patient having a mild hepatic impairment results in an AUC0-∞ that is 10-50% greater than that resulting from administering herombopag to the patient having normal liver function.

### Claim 8 (depends on 6)

The method according to claim 6, wherein: a therapeutically effective amount of the herombopag or the pharmaceutically acceptable salt thereof is administered to the patient having a moderate hepatic impairment, wherein administering herombopag to the patient having a moderate hepatic impairment results in an AUC0-∞ that is 30%-130% greater than that resulting from administering herombopag to the patient having normal liver function.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the patient is in need of administration of the herombopag or the pharmaceutically acceptable salt thereof to achieve and maintain a platelet count of ≥50×109/L.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the herombopag or the pharmaceutically acceptable salt thereof is administered to the patient to treat thrombocytopenia.

### Claim 11 (depends on 1)

The method according to claim 1 wherein the herombopag or the pharmaceutically acceptable salt thereof is herombopag diethanolamine salt.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the herombopag or the pharmaceutically acceptable salt thereof is administered at a dose of 1-30 mg.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the herombopag or the pharmaceutically acceptable salt thereof is administered in the form of a pharmaceutical composition.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the composition comprises a therapeutically effective amount of herombopag or the pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 2)

The method according to claim 2, wherein the initial dose of the herombopag or the pharmaceutically acceptable salt thereof administered to the patient having a moderate hepatic impairment is 20%-80% less than the initial dose administered to the patient having normal liver function or a mild hepatic functional impairment.

### Claim 16 (depends on 2)

The method according to claim 2, wherein the initial dose of the herombopag or the pharmaceutically acceptable salt thereof administered to the patient having a moderate hepatic impairment is 30%-70% less than the initial dose administered to the patient having normal liver function or a mild hepatic functional impairment.

### Claim 17 (depends on 6)

The method according to claim 6, wherein a therapeutically effective amount of the herombopag or the pharmaceutically acceptable salt thereof is administered to the patient having a mild hepatic impairment, wherein administering herombopag to the patient having a mild hepatic impairment results in an AUC0-∞ that is 15%-30% greater than that resulting from administering herombopag to the patient having normal liver function.

### Claim 18 (depends on 2)

The method according to claim 2, wherein the patient is in need of administration of the herombopag or the pharmaceutically acceptable salt thereof to achieve and maintain a platelet count of ≥50×109/L.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the herombopag or the pharmaceutically acceptable salt thereof is administered to the patient to treat thrombocytopenia, wherein the thrombocytopenia is selected from the group consisting of thrombocytopenia in the patient caused by immune thrombocytopenia, aplastic anemia, severe aplastic anemia, chronic liver diseases, or chemotherapy.

### Claim 20 (depends on 1)

The method according to claim 1, wherein the herombopag or the pharmaceutically acceptable salt thereof is administered at a dose of 2.5 mg, 3.75 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg.
